Wednesday, October 14, 2026

Emerson Electric Company And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

August 29, 2021

Emerson Electric Company  And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) - Emerson Electric Company (EMR), Johnson & Johnson (JNJ), Methanex Corporation (MEOH) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Emerson Electric Company (EMR)

12.1% sales growth and 25.77% return on equity

Emerson Electric Co., a technology and engineering company, provides solutions to industrial, commercial, and consumer markets worldwide.

Emerson Electric Company's sales growth this year is anticipated to be 9.7% and 6.5% for next year.

Year-on-year quarterly revenue growth grew by 6.5%, now sitting on 17.06B for the twelve trailing months.

Volume

Today's last reported volume for Emerson Electric Company is 1979790 which is 12.77% below its average volume of 2269770.

Emerson Electric Company's sales growth is a negative 0% for the present quarter and 12.1% for the next. The company's growth estimates for the present quarter and the next is 22.5% and 8.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 25.77%.

Volatility

Emerson Electric Company's last day, last week, and last month's current volatility was 0.06%, 0.59%, and 0.74%, respectively.

Emerson Electric Company's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.70% (day), 1.13% (last week), and 1.60% (last month), respectively.

Emerson Electric Company's Stock Yearly Top and Bottom Value

Emerson Electric Company's stock is valued at $104.77 at 06:22 EST, below its 52-week high of $105.02 and way higher than its 52-week low of $63.16.

Emerson Electric Company's Moving Average

Emerson Electric Company's value is above its 50-day moving average of $99.75 and way higher than its 200-day moving average of $94.01.

2. Johnson & Johnson (JNJ)

11.2% sales growth and 23.78% return on equity

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide.

Johnson & Johnson's sales growth this year is anticipated to be 14.4% and 3.7% for next year.

Year-on-year quarterly revenue growth grew by 7.9%, now sitting on 84.21B for the twelve trailing months.

Volume

Today's last reported volume for Johnson & Johnson is 6921120 which is 12.38% above its average volume of 6158630.

Johnson & Johnson's sales growth is a negative 0% for the present quarter and 11.2% for the next. The company's growth estimates for the ongoing quarter and the next is 7.3% and 20.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.78%.

Volatility

Johnson & Johnson's last day, last week, and last month's current volatility was 0.54%, 0.80%, and 0.58%, respectively.

Johnson & Johnson's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.97% (day), 1.01% (last week), and 0.99% (last month), respectively.

Johnson & Johnson's Stock Yearly Top and Bottom Value

Johnson & Johnson's stock is valued at $172.93 at 06:22 EST, under its 52-week high of $179.92 and way higher than its 52-week low of $133.65.

Johnson & Johnson's Moving Average

Johnson & Johnson's value is higher than its 50-day moving average of $172.55 and higher than its 200-day moving average of $166.31.

Previous days news about Johnson & Johnson(JNJ)

  • According to Bloomberg Quint on Wednesday, 25 August, "We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson Covid-19 vaccine, boosting eight months or longer after the primary single-dose vaccination," Mammen said in a statement."
  • According to Business Insider on Tuesday, 24 August, "Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced that Encision has signed a Supply Agreement ("Agreement") with Auris Health, Inc. ("Auris"), part of the Johnson & Johnson Medical Devices Companies."

3. Methanex Corporation (MEOH)

11.1% sales growth and 9.15% return on equity

Methanex Corporation produces and supplies methanol in North America, the Asia Pacific, Europe, and South America.

Methanex Corporation's sales growth this year is anticipated to be 48.3% and a negative 12.7% for next year.

Year-on-year quarterly revenue growth grew by 108.5%, now sitting on 3.48B for the twelve trailing months.

Volume

Today's last reported volume for Methanex Corporation is 210801 which is 7.93% below its average volume of 228965.

Methanex Corporation's sales growth for the next quarter is 11.1%. The company's growth estimates for the ongoing quarter and the next is 207.8% and 446.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.15%.

Volatility

Methanex Corporation's last day, last week, and last month's current volatility was 5.86%, 3.77%, and 2.38%, respectively.

Methanex Corporation's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.62% (day), 3.99% (last week), and 3.76% (last month), respectively.

Methanex Corporation's Stock Yearly Top and Bottom Value

Methanex Corporation's stock is valued at $34.87 at 06:22 EST, way below its 52-week high of $49.27 and way above its 52-week low of $21.60.

Methanex Corporation's Moving Average

Methanex Corporation's value is above its 50-day moving average of $33.00 and under its 200-day moving average of $36.34.

4. Cathay General Bancorp (CATY)

9% sales growth and 11.61% return on equity

Cathay General Bancorp operates as the holding company for Cathay Bank that offers various commercial banking products and services to individuals, professionals, and small to medium-sized businesses in the United States.

Cathay General Bancorp's sales growth this year is expected to be 7.8% and 5.8% for next year.

Year-on-year quarterly revenue growth grew by 35.6%, now sitting on 626.21M for the twelve trailing months.

Volume

Today's last reported volume for Cathay General Bancorp is 266151 which is 12.6% below its average volume of 304545.

Cathay General Bancorp's sales growth for the next quarter is 9%. The company's growth estimates for the present quarter and the next is 26.8% and 1.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.61%.

Volatility

Cathay General Bancorp's last day, last week, and last month's current volatility was 1.10%, 1.04%, and 1.27%, respectively.

Cathay General Bancorp's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.53% (day), 1.97% (last week), and 2.46% (last month), respectively.

Cathay General Bancorp's Stock Yearly Top and Bottom Value

Cathay General Bancorp's stock is valued at $39.69 at 06:22 EST, way under its 52-week high of $45.19 and way higher than its 52-week low of $20.59.

Cathay General Bancorp's Moving Average

Cathay General Bancorp's value is above its 50-day moving average of $38.15 and under its 200-day moving average of $40.16.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com